AstraZeneca Blames Trial Design for Phase 3 Bone Disease Drug Failure

· Health · United Kingdom

AstraZeneca has attributed the Phase 3 failure of its enzyme replacement therapy for a genetic bone disease to the way the trial was designed, according to new details from the study reported by Endpoints News. The company says the test missed its goals because of how the trial was composed, rather than because of the drug itself, as the drugmaker seeks to keep the program alive. The disclosure adds to a string of late-stage setbacks for the British pharmaceutical group and matters for the rare-disease field, where enzyme replacement therapies target small patient populations and trial design is often the difference between approval and failure. AstraZeneca has not yet said whether it will run a new study or change the treatment's development path.

Why it matters：Trial design is a recurring reason for late-stage failures in rare disease, and AstraZeneca's explanation will shape whether regulators and investors accept another attempt at the program.

Key points

  • The drug is an enzyme replacement therapy for a genetic bone disease.
  • AstraZeneca says the trial missed its goals because of how it was composed.
  • The company is seeking to keep the program going despite the Phase 3 miss.

Sources (original reporting)

More stories from this day